
STORM secures $56m financing for sarcoma treatment
Biotechnology company STORM Therapeutics has announced it has secured $56 million in a Series C financing to support its sarcoma treatment. The proceeds will support the advancement of STC-15, a first‑in‑class, oral small-molecule inhibitor of METTL3. This extends to funding the company’s Phase II monotherapy study… Read More




